ArticleArthritis & rheumatology (Hoboken, N.J.)2019
All-Cause and Cause-Specific Mortality Trends of End-Stage Renal Disease Due to Lupus Nephritis From 1995 to 2014.
Article in Arthritis & rheumatology (Hoboken, N.J.), 2019. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 18 papers, 2 of them syntheses that pooled it.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
18 citing papers in PubMed, 2 syntheses or guidelines pooled it, 47 citations in OpenAlex.
- Multiplicative Impact of Adverse Social Determinants of Health on Outcomes in Lupus Nephritis: A Meta-analysis and Systematic Review.Arthritis care & research · 2024Pooled it
- Effectiveness and safety of tripterygium glycosides tablet for lupus nephritis: a systematic review and Meta-analysis.Journal of traditional Chinese medicine = Chung i tsa chih ying wen pan · 2022Pooled it
- Article
- Serum fatty acid profiles in systemic lupus erythematosus and patient reported outcomes: The Michigan Lupus Epidemiology & Surveillance (MILES) Program.Frontiers in immunology · 2024Article
- Spatial proteomics landscape and immune signature analysis of renal sample of lupus nephritis based on laser-captured microsection.Inflammation research : official journal of the European Histamine Research Society ... [et al.] · 2023Article
- Treatment of lupus nephritis: consensus, evidence and perspectives.Nature reviews. Rheumatology · 2023Review
- Lupus Nephritis: Improving Treatment Options.Drugs · 2022Review
- All-cause and cause-specific mortality in systemic lupus erythematosus: a population-based study.Rheumatology (Oxford, England) · 2021Article
- Chronic use of hydroxychloroquine did not protect against COVID-19 in a large cohort of patients with rheumatic diseases in Brazil.Advances in rheumatology (London, England) · 2021Observational
- Renal disorders in rheumatologic diseases: the spectrum is changing (Part 1: connective tissue diseases).Journal of nephrology · 2021Review
- Renal deposits of complement factors as predictors of end-stage renal disease and death in patients with lupus nephritis.Rheumatology (Oxford, England) · 2020Article
- Accelerating Medicines Partnership: Organizational Structure and Preliminary Data From the Phase 1 Studies of Lupus Nephritis.Arthritis care & research · 2020Review
- Targeting glycosphingolipid metabolism as a potential therapeutic approach for treating disease in female MRL/lpr lupus mice.PloS one · 2020Article
- Individualizing Therapy in Lupus Nephritis.Kidney international reports · 2019Review
- Proteomic profiling of urine: implications for lupus nephritis.Expert review of proteomics · 2019Review
- Challenges and Opportunities for Consistent Classification of Human B Cell and Plasma Cell Populations.Frontiers in immunology · 2019Review
- Clinical efficacy and safety of rituximab in lupus nephritis.Drug design, development and therapy · 2019Article
- Article
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
6 authors at 3 institutions in 1 country.
Funding
Abstract
objectiveA prior study showed that premature mortality among patients with end-stage renal disease (ESRD) due to lupus nephritis (LN) persisted in the US between 1995 and 2006. The present study was undertaken to extend this analysis through 2014 to examine more recent trends, including key cause-specific mortality trends.
methodsUsing the national registry of patients with ESRD, we identified all patients with incident ESRD due to LN between January 1, 1995 and December 31, 2014, divided into four 5-year cohorts of ESRD onset by calendar year (1995-1999, 2000-2004, 2005-2009, 2010-2014). We assessed mortality within each cohort. Temporal trends in all-cause mortality and cause-specific mortality were examined, adjusting for covariates.
resultsWe identified 20,974 individuals with incident ESRD due to LN from 1995 through 2014. The mortality rate per 100 patient-years declined from 11.1 (95% confidence interval [95% CI] 10.4-11.8) in 1995-1999 to 6.7 (95% CI 6.2-7.2) in 2010-2014 (P for trend < 0.01). Adjusted mortality hazard ratios in 2010-2014, compared with 1995-1999, were 0.68 (95% CI 0.58-0.78) for white patients, 0.67 (95% CI 0.57-0.78) for African American patients, and 0.51 (95% CI 0.38-0.69) for Hispanic patients. Deaths from cardiovascular disease (CVD) and infection declined by 44% and 63%, respectively, from 1995-1999 to 2010-2014 (P for trend < 0.01 for both).
conclusionIn the more recent years of the period 1995-2014, there was a considerable reduction in all-cause mortality among white, African American, and Hispanic patients, with reduced risk of death from CVD and infection. Collectively, these trends provide an important benchmark of improving care in this high-risk population.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.